drug
nirsevimab
Marketedupdated 3mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
all catalysts(5)
approval · 5
Jul 17, 2023
approval
$AZN156.58+0.08%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Feb 23, 2024
approval
$AZN156.58+0.08%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Aug 22, 2024
approval
$AZN156.58+0.08%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Oct 20, 2025
approval
$AZN156.58+0.08%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Apr 7, 2026
approval
$AZN156.58+0.08%
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Trials studying nirsevimab
- —An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia
- —RSV Immunisation Status in Queensland (Australia)
- phase3A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
- phase3Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China
- phase4Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India
- phase2Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants
- —A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
- EP1A Clinical Trial of SIBP-A16 Injection in Healthy Adults
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that